AMSTERDAM: BenevolentAI, a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, today announced a strategic review approved by its Board of Directors. The Company said it is further evolving its differentiated technology platform and launching a new suite of products to capitalise on the vast potential of AI-driven…